.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Healthtrust
AstraZeneca
Accenture
Chubb
Fuji
Johnson and Johnson
Cantor Fitzgerald
Fish and Richardson

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020977

« Back to Dashboard
NDA 020977 describes ZIAGEN, which is a drug marketed by Viiv Hlthcare and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ZIAGEN profile page.

The generic ingredient in ZIAGEN is abacavir sulfate. There are eleven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the abacavir sulfate profile page.

Summary for NDA: 020977

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 020977

Suppliers and Packaging for NDA: 020977

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZIAGEN
abacavir sulfate
TABLET;ORAL 020977 NDA ViiV Healthcare Company 49702-221 49702-221-18 1 BOTTLE in 1 CARTON (49702-221-18) > 60 TABLET, FILM COATED in 1 BOTTLE
ZIAGEN
abacavir sulfate
TABLET;ORAL 020977 NDA ViiV Healthcare Company 49702-221 49702-221-44 6 BLISTER PACK in 1 DOSE PACK (49702-221-44) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 300MG BASE
Approval Date:Dec 17, 1998TE:ABRLD:Yes
Patent:6,294,540*PEDPatent Expiration:Nov 14, 2018Product Flag?Substance Flag?Delist Request?Y
Regulatory Exclusivity Expiration:Mar 23, 2018
Regulatory Exclusivity Use:ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION

Expired Orange Book Patents for NDA: 020977

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
ZIAGEN
abacavir sulfate
TABLET;ORAL020977-001Dec 17, 19985,034,394*PED► Subscribe
Viiv Hlthcare
ZIAGEN
abacavir sulfate
TABLET;ORAL020977-001Dec 17, 19985,089,500*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
McKinsey
Dow
Federal Trade Commission
Express Scripts
Boehringer Ingelheim
AstraZeneca
Colorcon
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot